Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!

SIMPLE SUMMARY: Poly (ADP-ribose) polymerase inhibitors (PARPis) have been recently approved by international medicine agencies for the treatment of ovarian cancer patients with either BRCA pathogenic variants or homologous recombination deficiency (HRD), changing the ovarian cancer treatment landsc...

Descripción completa

Detalles Bibliográficos
Autores principales: Magliacane, Gilda, Brunetto, Emanuela, Calzavara, Silvia, Bergamini, Alice, Pipitone, Giovanni Battista, Marra, Giovanna, Redegalli, Miriam, Grassini, Greta, Rabaiotti, Emanuela, Taccagni, Gianluca, Pecciarini, Lorenza, Carrera, Paola, Mangili, Giorgia, Doglioni, Claudio, Cangi, Maria Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817883/
https://www.ncbi.nlm.nih.gov/pubmed/36612041
http://dx.doi.org/10.3390/cancers15010043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817883/
https://www.ncbi.nlm.nih.gov/pubmed/36612041
http://dx.doi.org/10.3390/cancers15010043

Ejemplares similares